VOYAGER DIGITAL LT
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 162
- Market Cap
- $361.5M
- Introduction
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants with Early Alzheimer's Disease
Phase 1
Recruiting
- Conditions
- Alzheimer's Disease (AD)
- Interventions
- Drug: Placebo Comparator
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Voyager Therapeutics
- Target Recruit Count
- 52
- Registration Number
- NCT06874621
- Locations
- 🇺🇸
VYGR Site 840018, Los Angeles, California, United States
🇺🇸VYGR Site 840016, Orange, California, United States
🇺🇸VYGR Site 840022, San Francisco, California, United States
Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease
Phase 1
Withdrawn
- Conditions
- Huntington Disease
- Interventions
- Genetic: Intraparenchymal rAAV1 - (mi)RNA HTT
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Voyager Therapeutics
- Registration Number
- NCT04885114
© Copyright 2025. All Rights Reserved by MedPath